Skip to main content
Top
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Hematuria | Case report

A potential pathogenic role of interleukin-6 in a child with ANCA-negative pauci-immune crescentic glomerulonephritis: case report and literature review

Authors: Ling Hou, Lu Yin, Yubin Wu, Chengguang Zhao, Yue Du

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

Crescentic glomerulonephritis is a disease characterized by severe glomerular injuries that is classified into five different pathological types. Patients with type V disease have pauci-immune crescentic glomerulonephritis (PICGN) that is negative for anti-neutrophil cytoplasmic autoantibodies (ANCAs). There are limited clinical data on the manifestations, treatment, and prognosis of type V crescentic glomerulonephritis, especially in children.

Case presentation

A 13-year-old girl who had an intermittent fever for more than 10 months was admitted to our hospital. She had no gross hematuria, oliguria, edema, or hypertension, but further tests indicated a decreased glomerular filtration rate, hematuria, proteinuria, and an elevated level of IL-6. The antinuclear antibody spectrum test was positive at 1:1000, and the ANCA and anti-glomerular basement membrane antibody tests were negative. A renal biopsy confirmed the diagnosis of ANCA-negative PICGN. We administered methylprednisolone pulse therapy with intravenous cyclophosphamide and oral mycophenolate mofetil. At the 3-month follow-up, her urine protein level was significantly lower, and her serum creatinine level was in the normal range.

Conclusions

Fever may be an extrarenal manifestation of ANCA-negative PICGN, and IL-6 may play a role in the pathogenesis of this disease. Early methylprednisolone pulse therapy with an immunosuppressant may reduce symptoms and improve prognosis.
Literature
2.
go back to reference Prakash J, Patel PS, Prakash S, Iqbal M, Sharma SS, Singh S, et al. Etiopathological study of Crescentic glomerulonephritis and its outcome: a retrospective analysis. J Assoc Physicians India. 2019;67(11):18–21.PubMed Prakash J, Patel PS, Prakash S, Iqbal M, Sharma SS, Singh S, et al. Etiopathological study of Crescentic glomerulonephritis and its outcome: a retrospective analysis. J Assoc Physicians India. 2019;67(11):18–21.PubMed
3.
go back to reference Parmar MS, Bashir K: Crescentric Glomerulonephritis. StatPearls. edn. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021. Parmar MS, Bashir K: Crescentric Glomerulonephritis. StatPearls. edn. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
8.
go back to reference Maliakkal JG, Hicks MJ, Michael M, Selewski DT, Twombley K, Rheault MN, et al. Renal survival in children with glomerulonephritis with crescents: a pediatric nephrology research consortium cohort study. J Clin Med. 2020;9(8). https://doi.org/10.3390/jcm9082385. Maliakkal JG, Hicks MJ, Michael M, Selewski DT, Twombley K, Rheault MN, et al. Renal survival in children with glomerulonephritis with crescents: a pediatric nephrology research consortium cohort study. J Clin Med. 2020;9(8). https://​doi.​org/​10.​3390/​jcm9082385.
Metadata
Title
A potential pathogenic role of interleukin-6 in a child with ANCA-negative pauci-immune crescentic glomerulonephritis: case report and literature review
Authors
Ling Hou
Lu Yin
Yubin Wu
Chengguang Zhao
Yue Du
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02504-w

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine